MVML, INC.

MVML, INC. was paid $27.53M by Medicaid between Mar 2021 and Nov 2023, across 11 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 86% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in California

Rank by total paid#34 of 561

Median peer was paid$222K

This provider vs. median124×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2021	29,335	$759K
2022	520,506	$24.82M
2023	26,006	$1.95M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	86%	351,890	176,580	$23.78M
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	7.9%	131,004	63,071	$2.18M
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	2.4%	4,694	2,522	$655K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	2.0%	81,015	44,949	$548K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	1.2%	6,453	3,590	$332K
87811	Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19)	<1%	649	384	$25K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	28	28	$5K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	31	31	$918.31
87581		<1%	28	28	$381.94
87498		<1%	27	27	$381.94
87486		<1%	28	28	$381.94

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialAZARRAGA, KRISTINE (DIRECTOR OF COMPLIANCE)